677 related articles for article (PubMed ID: 30352608)
21. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study.
Chang JH; Wada M; Anderson NJ; Lim Joon D; Lee ST; Gong SJ; Gunawardana DH; Sachinidis J; O'Keefe G; Gan HK; Khoo V; Scott AM
Acta Oncol; 2013 Nov; 52(8):1723-9. PubMed ID: 23317145
[TBL] [Abstract][Full Text] [Related]
22. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
[TBL] [Abstract][Full Text] [Related]
23. [The use of PET/CT in radiotherapy of patients with non-small cell lung cancer].
Lõcsei Z; Hideghéty K; Farkas R; Bellyei S; Sárosi V; Sebestyén K; Sebestyén Z; Kovács P; Mangel L
Magy Onkol; 2011 Nov; 55(4):274-80. PubMed ID: 22128310
[TBL] [Abstract][Full Text] [Related]
24. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
Lee NY; Mechalakos JG; Nehmeh S; Lin Z; Squire OD; Cai S; Chan K; Zanzonico PB; Greco C; Ling CC; Humm JL; Schöder H
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):2-13. PubMed ID: 17869020
[TBL] [Abstract][Full Text] [Related]
25. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
26. Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study.
Møller DS; Nielsen TB; Brink C; Hoffmann L; Lutz CM; Drøgemüller Lund M; Hansen O; Schytte T; Khalil AA; Knap MM; Nyhus CH; Ottosson W; Sibolt P; Borissova S; Josipovic M; Persson G; Appelt AL
Radiother Oncol; 2017 Aug; 124(2):311-317. PubMed ID: 28688525
[TBL] [Abstract][Full Text] [Related]
27. Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis.
Eze C; Taugner J; Roengvoraphoj O; Schmidt-Hegemann NS; Käsmann L; Wijaya C; Belka C; Manapov F
Radiat Oncol; 2019 Sep; 14(1):163. PubMed ID: 31484542
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer.
Chin AL; Kumar KA; Guo HH; Maxim PG; Wakelee H; Neal JW; Diehn M; Loo BW; Gensheimer MF
Clin Lung Cancer; 2018 Sep; 19(5):e581-e588. PubMed ID: 29759331
[TBL] [Abstract][Full Text] [Related]
29. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
[TBL] [Abstract][Full Text] [Related]
30. Consequences of additional use of contrast-enhanced (18)F-FDG PET/CT in target volume delineation and dose distribution for pancreatic cancer.
Li XX; Liu NB; Zhu L; Yuan XK; Yang CW; Ren P; Gong LL; Zhao LJ; Xu WG; Wang P
Br J Radiol; 2015 Jul; 88(1051):20140590. PubMed ID: 25939819
[TBL] [Abstract][Full Text] [Related]
31. Use of FDG-PET to guide dose prescription heterogeneity in stereotactic body radiation therapy for lung cancers with volumetric modulated arc therapy: a feasibility study.
de Figueiredo BH; Antoine M; Trouette R; Lagarde P; Petit A; Lamare F; Hatt M; Fernandez P
Radiat Oncol; 2014 Dec; 9():300. PubMed ID: 25534014
[TBL] [Abstract][Full Text] [Related]
32. Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
Liu J; Li C; Hu M; Lu J; Shi X; Xing L; Sun X; Fu Z; Yu J; Meng X
Medicine (Baltimore); 2015 May; 94(17):e678. PubMed ID: 25929896
[TBL] [Abstract][Full Text] [Related]
33. Volumetric-modulated arc therapy (RapidArc) vs. conventional fixed-field intensity-modulated radiotherapy for ¹⁸F-FDG-PET-guided dose escalation in oropharyngeal cancer: a planning study.
Teoh M; Beveridge S; Wood K; Whitaker S; Adams E; Rickard D; Jordan T; Nisbet A; Clark CH
Med Dosim; 2013; 38(1):18-24. PubMed ID: 22841937
[TBL] [Abstract][Full Text] [Related]
34. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing.
Feng M; Kong FM; Gross M; Fernando S; Hayman JA; Ten Haken RK
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1228-34. PubMed ID: 19251094
[TBL] [Abstract][Full Text] [Related]
35. A planning study of radiotherapy dose escalation of PET-active tumour volumes in non-small cell lung cancer patients.
Møller DS; Khalil AA; Knap MM; Muren LP; Hoffmann L
Acta Oncol; 2011 Aug; 50(6):883-8. PubMed ID: 21767188
[TBL] [Abstract][Full Text] [Related]
36. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer.
Vanuytsel LJ; Vansteenkiste JF; Stroobants SG; De Leyn PR; De Wever W; Verbeken EK; Gatti GG; Huyskens DP; Kutcher GJ
Radiother Oncol; 2000 Jun; 55(3):317-24. PubMed ID: 10869746
[TBL] [Abstract][Full Text] [Related]
37. Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center.
Rosen LR; Fischer-Valuck BW; Katz SR; Durci M; Wu HT; Syh J; Syh J; Patel B
Tumori; 2014; 100(1):42-8. PubMed ID: 24675490
[TBL] [Abstract][Full Text] [Related]
38. Dose escalation for locally advanced lung cancer using adaptive radiation therapy with simultaneous integrated volume-adapted boost.
Weiss E; Fatyga M; Wu Y; Dogan N; Balik S; Sleeman W; Hugo G
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):414-9. PubMed ID: 23523321
[TBL] [Abstract][Full Text] [Related]
39. Validation of dose painting of lung tumours using alanine/EPR dosimetry.
Knudtsen IS; Svestad JG; Skaug Sande EP; Rekstad BL; Rødal J; van Elmpt W; Öllers M; Hole EO; Malinen E
Phys Med Biol; 2016 Mar; 61(6):2243-54. PubMed ID: 26913997
[TBL] [Abstract][Full Text] [Related]
40. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL;
Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]